MPTP: Insights into parkinsonian neurodegeneration

Neurotoxicology and Teratology

Volumn 24, Issue 5, 2002, Pages 607-620

  Speciale, Samuel G ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Dopamine; MPTP; Neurodegeneration; Neurotoxicity; Oxidative stress; Parkinsonism

Indexed keywords

ACETYLCYSTEINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DOPA; GLUTATHIONE; PARKIN; SELEGILINE;

BRAIN; CELL DEATH; CLINICAL TRIAL; CROSS FERTILIZATION; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GENETICS; HUMAN; IMAGING SYSTEM; MITOCHONDRION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIOXIDANTS; APOPTOSIS; DOPAMINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NERVE DEGENERATION; NEURONS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

ANIMALIA; PARKINSONIA; PRIMATES;

EID: 0036716889     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(02)00222-2     Document Type: Review

References (193)

1. Melatonin is protective against MPTP-induced striatal and hippocampal lesions
2. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain?
3. Peptides and Parkinson's disease
4. Participation of manganese-superoxide dismutase in the neuroprotection exerted by copper sulfate against 1-methyl-4-phenylpyridinium neurotoxicity
5. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid and MPTP
6. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
7. A prospective study of caffeine consumption and risk of Parkinson's disease in men and women
8. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice
9. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease
10. + and paraquat in frogs and in vitro
11. Ecogenetics of Parkinson's disease: Prevalence and environmental aspects in rural areas
12. Degradation of α-synuclein by proteosome
13. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
14. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
15. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter
16. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease
17. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics
18. Neurogenetic correlates of Parkinson's disease: Apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism
19. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
20. Biochemical and pathological effects of MPTP in the rhesus monkey
21. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57BL/6 mice
22. Parkinson's disease is not one disease
23. Inhibition of 1-methyl-4-phenylpyridinium ion and dopamine in striatal synaptosomes by tobacco smoke components
24. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism
25. Neuroprotection in the MPTP parkinsonian C57BL/6 mouse model by a compound isolated from tobacco
26. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system
27. Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease
28. Genetic polymorphisms in Parkinson's disease
29. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease
30. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults
31. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
32. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia
33. Monoamine oxidase and oxidative stress at dopaminergic synapses
34. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson's disease
35. Paraquat: A useful tool for the in vivo study of mechanisms of neuronal cell death
36. Understanding Parkinson disease
37. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity
38. + binds to neuromelanin
39. 11C-tetrabenazine
40. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
41. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo
42. Proteosome inhibition in oxidative stress neurotoxicity: Implications for heat shock proteins
43. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
44. Participation of Par-4 in degeneration of dopaminergic neurons in models of Parkinson's disease
45. Is Parkinson's disease acquired or inherited?
46. Parkinson's disease: Evidence against a toxic etiology and for an alternative theory
47. Low frequency of α-synuclein in Parkinson's disease
48. The protective effects of PBN against MPTP toxicity are independent of hydroxyl radical trapping
49. The N-methyl-D-aspartate antagonist MK-801 fails to protect dopaminergic neurons from 1-methyl-4-phenylpyridinium toxicity in vitro
50. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations
51. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
52. Imaging the vesicular monoamine transporter
53. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
54. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat
55. Nucleosomal DNA fragmentation in 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-treated mice
56. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice
57. N, N′-bis-dibenzyl ethylenediaminediacetic acid (DBED): A site-specific hydroxyl radical scavenger acting as an "oxidative stress activatable" iron chelator in vitro
58. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system
59. Free radical scavengers: Chemical concepts and clinical relevance
60. Molecular genetics of Parkinson's disease
61. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization
62. Tau and α-synuclein in neurodegenerative diseases
63. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine administration to several strains of mice
64. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study
65. Antiparkinsonian effect of a new selective adenosine A-2A receptor antagonist in MPTP-treated monkeys
66. Bcl-2 family members and the mitochondria in apoptosis
67. Effects of R- and S-apomorphine on MPTP-induced nigrostriatal dopamine neuronal loss
68. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: Relevance to Parkinson's disease
69. Parkinson's disease: The apoptosis hypothesis revisited
70. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis
71. Increase in bax expression in substantia nigra following MPTP treatment of mice
72. Zur pathologischen anatomie des senilen und des parkinsonistischen tremor
73. Differential neurotoxicity of 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources
74. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin
75. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice
76. Inhibition of monoamine oxidase produces protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
77. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity
78. +-induced neurotoxicity in rodents
79. Smoking and Parkinson's disease: A case-controlled study in Germany
80. Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons. A hypothesis for cell death in aging and disease
81. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis
82. Neuronal vulnerability in Parkinson's disease
83. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice
84. Brain dopamine in Parkinson's disease and other neurological disturbances
85. Fc epsilon RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells
86. Age-dependent effects of 1-methyl-4-phenyl-tetrahydropyridine (MPTP)
87. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity
88. Iron-melanin complex in substantia nigra of parkinsonian brains: An X-ray microanalysis
89. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset
90. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
91. +) neurotoxicity in rats
92. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease
93. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice
94. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
95. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
96. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
97. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein-E genotype
98. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells
99. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Aβ stabilization
100. MPTP: Current concepts and controversies
101. Parkinson's disease in a chemist working with MPTP
102. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
103. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
104. Evaluation of the capability of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pyridine derivatives to evoke parkinsonism
105. The ubiquitin pathway in Parkinson's disease
106. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
107. Pesticides and Parkinsonism: Is there an etiological link?
108. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors
109. Alpha synuclein is selectively redistributed in the substantia nigra of MPTP-treated mice
110. CDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: Implication for idiopathic Parkinson's disease
111. Pathological basis for neurotransmitter changes in Parkinson's disease
112. The pathology of the human locus coeruleus
113. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice
114. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
115. Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism
116. Novel free radical spin traps protect against malonate and MPTP neurotoxicity
117. S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity
118. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease
119. Inflammation in Parkinson's disease
120. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease
121. Dysfunction of rat forebrain astrocytes in culture alters cytokine release and neurotrophic factor release
122. Neurotoxicity of levodopa on catecholamine rich neurons
123. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease
124. Familial Parkinson's disease: Α-synuclein and parkin
125. +) in isolated mitochondria from mouse brains
126. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease
127. SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
128. Mechanism of MPTP neurotoxicity
129. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta
130. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
131. Cell death induced by MPTP, a substrate for monoamine oxidase B
132. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
133. Abnormalities of the electron transport chain in idiopathic Parkinson's disease
134. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse
135. Differential expression of two vesicular monoamine transporters
136. Mutations in the α-synuclein gene identified in families with Parkinson's disease
137. Environmental risk factors and Parkinson's disease: A meta-analysis
138. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease
139. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
140. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced neurotoxicity
141. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP
142. +, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase
143. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism
144. +
145. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria
146. Further studies in xenobiotic metabolism and Parkinson's disease
147. Dopamine agonists: Their role in the management of Parkinson's disease
148. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice
149. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells
150. Is there neuroprotection in Parkinson syndrome?
151. Parkinson's disease - A multifactorial neurodegenerative disorder
152. Neurotoxicity by L-DOPA and dopamine: Neuroprotective role of melatonin
153. +
154. Association of coffee and caffeine intake with the risk of Parkinson disease
155. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins
156. Evidence for mitochondrial dysfunction in Parkinson's disease - A critical appraisal
157. Mitochondrial complex I deficiency in Parkinson's disease
158. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
159. Introduction: Targeted modulation of neuronal apoptosis: A double-edged sword?
160. Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP). Parkinson study group
161. DATATOP: A decade of neuroprotective inquiry. Parkinson study group. Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism
162. Parkinson's disease
163. +-induced parkinsonism is determined by glia
164. MPTP: A neurotoxin relevant to the pathophysiology of Parkinson's disease
165. The neurotoxin 1-methyl-4-phenylpyridinum is sequestered within neurons that contain the vesicular monoamine transporter
166. TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single dose of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine
167. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium
168. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinum neurotoxicity in vivo in rat striata
169. Neurochemical and neuroreceptor imaging with PET in Parkinson's disease
170. Cytochrome P450 in neurodegeneration and Parkinson's disease
171. Mitochondria and Parkinson's disease
172. Parkinson disease in twins: An etiologic study
173. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
174. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
175. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
176. + and studies on its chemical and biochemical reactivity
177. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity
178. + neurotoxicity by N-methyl-D-aspartate antagonists
179. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
180. α-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
181. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice expressing the baculoviral caspase inhibitor p35
182. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium
183. (-)-2-Oxo-4-thiazolidine carboxylic acid attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity
184. A curtain riser
185. + toxicity in nigral dopaminergic neurones
186. Relationship of complement-activated oligodendrocytes to reactive microglia and neuronal pathology in neurodegenerative disease
187. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms
188. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity
189. Depletion of glutathione in brainstems of mice by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment
190. 3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice
191. + is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: A model of natural resistance to MPTP toxicity